Research programme: 11-beta hydroxysteroid dehydrogenase type-1 inhibitors - Equis & Zaroo

Drug Profile

Research programme: 11-beta hydroxysteroid dehydrogenase type-1 inhibitors - Equis & Zaroo

Alternative Names: EQ-1280

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator EQUIS & ZAROO
  • Class
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in South Korea
  • 24 Mar 2011 Preclinical trials in Diabetes mellitus in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top